

Sarcoma Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



Sarcoma

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

First Line

Second Line

Recurrent

UCI 21-03

Pembrolizumab + Stereotactic Body Radiation Therapy

Coord: N. Arechiga

Accrual: 6/8

EA7211

Surgery + Doxorubicin, Ifosfamide or
Doxorubicin, Decarbazine

Coord: B. Huynh

Accrual: 0/5

ETCTN 10556

Ipilimumab and Nivolumab +/-
Cabozantinib

Coord: B. Huynh

Accrual: 2/5

